Solutions with/in/sight: Catalytic Combinations for Prostate Cancer and Beyond

When: December 10, 2019, 7:00 pm - 8:00 pm
Where: Koch Institute for Integrative Cancer Research at MIT, 500 Main Street, Cambridge, MA

Learn how MIT cancer researchers are teaming up with clinical and biotech collaborators to combat resistant tumors in prostate cancer.

Illuminating the science behind an ongoing clinical trial, Professor Michael Yaffe and his clinical and biotech collaborators tell the story of how a synergistic drug combination discovered at the Koch Institute revived an all but forgotten drug class and shows great promise for combatting resistant tumors. Beth Israel Deaconess Medical Center’s David Einstein shares clinical perspectives from the trial, and Trovagene’s Mark Erlander talks about the Plk-1 inhibitor that proved crucial for the introduction of this combination into prostate cancer. Achieving more together than they ever could on their own, this dynamic team embodies the powerful synergy they are bringing to patients. Presenters: Michael B. Yaffe. MD, PhD Director, MIT Center for Precision Cancer Medicine David H. Koch Professor of Science Professor of Biology and Biological Engineering Jesse Patterson, PhD Postdoctoral Fellow, Yaffe Lab, Koch Institute David Einstein, MD Medical Oncologist, Beth Israel Deaconess Medical Center Instructor, Medicine, Harvard Medical School Mark Erlander, PhD Chief Scientific Officer, Trovagene Oncology Check-in opens at 6:45pm. Coffee & dessert will follow the presentations.

Learn more »

Connect With Us

Blog Facebook LinkedIn Twitter